Enterprise Value
6.395B
Cash
619M
Avg Qtr Burn
-105.4M
Short % of Float
16.75%
Insider Ownership
0.50%
Institutional Own.
-
Qtr Updated
03/31/24
Drug Pipeline
Powered by
![](/BPIQ_Pill.png)
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Aficamten (CK-274) (cardiac myosin inhibitor) Details Heart disease, Hypertrophic cardiomyopathies | NDA Submission | |
Omecamtiv Mecarbil (cardiac myosin activator) Details Pancreatic cancer, Heart disease, Heart failure | NDA FDA meeting | |
CK-4021586 (CK-586) (cardiac myosin inhibitor) Details Heart disease, Heart failure | Phase 2 Initiation | |
CK-3828136(CK-136) (cardiac troponin activator) Details Heart failure, Heart disease, Epilepsy | Phase 1 Data readout | |
Reldesemtiv (CK-601) (next-generation fast skeletal muscle troponin activator (FSTA)) Details Amyotrophic lateral sclerosis, Neurodegenerative disease | Failed Discontinued |